Orso Beatrice, Mattioli Pietro, Yoon Eun-Jin, Kim Yu Kyeong, Kim Heejung, Shin Jung Hwan, Kim Ryul, Famà Francesco, Brugnolo Andrea, Massa Federico, Chiaravalloti Agostino, Fernandes Mariana, Spanetta Matteo, Placidi Fabio, Pardini Matteo, Bauckneht Matteo, Morbelli Silvia, Lee Jee-Young, Liguori Claudio, Arnaldi Dario
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.
Neurophysiopathology Unit, IRCCS Ospedale Policlinico S. Martino, Genoa, Italy.
NPJ Parkinsons Dis. 2024 Oct 25;10(1):200. doi: 10.1038/s41531-024-00813-z.
The phenoconversion trajectory from idiopathic/isolated Rapid eye movement (REM) sleep behavior disorder (iRBD) towards either Parkinson's Disease (PD) or Dementia with Lewy Bodies (DLB) is currently uncertain. We investigated the capability of baseline brain [F]FDG-PET in differentiating between iRBD patients eventually phenoconverting to PD or DLB, by deriving the denovoPDRBD-related pattern (denovoPDRBD-RP) from 32 de novo PD patients; and the denovoDLBRBD-RP from 30 de novo DLB patients, both with evidence of RBD at diagnosis. To explore [F]FDG-PET phenoconversion trajectories prediction power, we applied these two patterns on a group of 115 iRBD patients followed longitudinally. At follow-up (25.6 ± 17.2 months), 42 iRBD patients progressed through overt alpha-synucleinopathy (21 iRBD-PD and 21 iRBD-DLB converters), while 73 patients remained stable at the last follow-up visit (43.2 ± 27.6 months). At survival analysis, both patterns were significantly associated with the phenoconversion trajectories. Brain [F]FDG-PET is a promising biomarker to study progression trajectories in the alpha-synucleinopathy continuum.
从特发性/孤立性快速眼动（REM）睡眠行为障碍（iRBD）向帕金森病（PD）或路易体痴呆（DLB）的表型转化轨迹目前尚不确定。我们通过从32例新发PD患者中推导新的PDRBD相关模式（denovoPDRBD-RP），以及从30例新发DLB患者中推导新的DLBRBD-RP（诊断时均有RBD证据），研究了基线脑[F]FDG-PET在区分最终表型转化为PD或DLB的iRBD患者方面的能力。为了探索[F]FDG-PET表型转化轨迹的预测能力，我们将这两种模式应用于一组115例纵向随访的iRBD患者。在随访（25.6±17.2个月）时，42例iRBD患者进展为明显的α-突触核蛋白病（21例iRBD-PD转化者和21例iRBD-DLB转化者），而73例患者在最后一次随访（43.2±27.6个月）时保持稳定。在生存分析中，两种模式均与表型转化轨迹显著相关。脑[F]FDG-PET是研究α-突触核蛋白病连续体进展轨迹的一种有前景的生物标志物。
